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Abstract: (n=293) 
Background and aims: It has been proposed that more use should be made of Bayes Factors in hypothesis 
testing in addiction research. Bayes Factors are the ratios of the likelihood of a specified hypothesis (e.g. an 
intervention effect within a given range) to another hypothesis (e.g. no effect). They are particularly 
important for differentiating lack of strong evidence for an effect and evidence for lack of an effect. This 
paper reviewed randomised trials reported in Addiction between January and June 2013 to assess how far 
Bayes Factors might improve the interpretation of the data. 
Methods: Seventy five effect sizes and their standard errors were extracted from 12 trials. Seventy three per 
cent (n=55) of these were non-significant (i.e. p>0.05). For each non-significant finding a Bayes Factor was 
calculated using a population effect derived from previous research. In sensitivity analyses, a further two 
Bayes Factors were calculated assuming clinically meaningful and plausible ranges around this population 
effect. 
Results: Twenty per cent (n=11) of the non-significant Bayes Factors were < 1/3rd and 3.6% (n=2) were > 3. 
The other 76.4% (n=42) of Bayes Factors were between 1/3rd and 3. Of these, 26 were in the direction of 
there being an effect (Bayes Factor >1 & <3); 12 tended to favour the hypothesis of no effect (Bayes Factor 
<1 & >1/3rd); and for 4 there was no evidence either way (Bayes Factor =1). In sensitivity analyses, 13.3% of 
Bayes Factors were <1/3rd (n=20), 62.7% (n=94) were between 1/3rd and 3 and 24.0% (n=36) were >3, showing 
good concordance with the main results. 
Conclusions: Use of Bayes Factors when analysing data from randomised trials of interventions in addiction 
research can provide important information that would lead to more precise conclusions than are typically 
obtained using currently prevailing methods. 
  
Introduction 
Bayesian statistical analyses are being increasingly used in addictions research and it has been proposed that 
this trend should accelerate (1). One important component of Bayesian analysis is the calculation of Bayes 
Factors, which overcome many of the problems of traditional frequentist statistics (2). One of these is the 
misinterpretation that p-values can be used to make claims of ‘no effect’ (3-5). P-values signal the 
extremeness of the data under the assumption of the null hypothesis and so only tell us the probability of a 
test statistic at least as extreme as the one observed . Thus, a p>0.05 may reflect evidence for ‘no effect’ or 
data insensitivity i.e. a failure to distinguish the null hypothesis from the alternative because, for example, 
the standard error (SE) is high.  
Bayes Factors are the ratio of the (average) likelihood of two hypotheses being correct given a set of data. 
When evaluating interventions, the two hypotheses are typically H1: that the intervention had a desired 
effect (for a given range of plausible sizes), or within a certain range, versus H0: that it had no effect. Thus a 
Bayes Factor is equivalent to a likelihood ratio (6) (averaged over different plausible effect sizes) and thus is 
often denoted as: 
𝐵𝑎𝑦𝑒𝑠 𝐹𝑎𝑐𝑡𝑜𝑟 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑜𝑓 𝑑𝑎𝑡𝑎 𝑔𝑖𝑣𝑒𝑛 𝐻1
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑜𝑓 𝑑𝑎𝑡𝑎 𝑔𝑖𝑣𝑒𝑛  𝐻0
=
𝑃(𝐷|𝐻1)
𝑃(𝐷|𝐻0)
 
which simply represents the probability of the data (D) given the alternative hypothesis divided by the 
probability of the data given the null hypothesis. 
Use of Bayes Factors has become more feasible in recent years following the development of online 
calculators (7) and R code (8, 9). Conventional cut-offs for the interpretation of Bayes Factors typically 
depend on those set by Jeffreys  in the 1930s, with a Bayes factor greater than 3, or else less than 1/3, 
representing sufficient evidence to be taken note of for the experimental and null hypotheses respectively; 
while values between roughly 1/3 and 3 indicate that the data are insensitive (see Table 1). 
 
Table 1: Jeffreys’ Bayes Factor cut-offs 
Bayes Factor Interpretation  
>100 Extreme evidence for the experimental hypothesis 
30-100 Very strong evidence for the experimental hypothesis 
10-30 Strong evidence for the experimental hypothesis 
3-10 Moderate evidence for the experimental hypothesis 
1-3 Anecdotal evidence for the experimental hypothesis 
1 No evidence 
1/3-1 Anecdotal evidence for the null hypothesis 
1/3-1/10 Moderate evidence for the null hypothesis 
1/10-1/30 Strong evidence for the null hypothesis 
1/30-1/100 Very strong evidence for the null hypothesis 
<1/100 Extreme evidence for the null hypothesis 
Note: The original label for 3< Bayes Factor<10 was “substantial evidence”. Lee & Wagenmakers changed it to moderate as they thought the original 
label sounded too decisive (3, 10).  
 
 This paper uses a set of randomised trials in the field of addiction to examine whether, and in what way, the 
conclusions may have been different had the authors calculated Bayes Factors in their analyses. This should 
be useful in future research to assess whether and when to use this form of analysis. 
Calculating Bayes Factors 
Several software packages are available including an online calculator developed by Zoltan Dienes 
(http://www.lifesci.sussex.ac.uk/home/Zoltan_Dienes/inference/Bayes.htm) and a modified version by John 
Christie using R code which allows one to adjust the quality of the estimation (8, 9). 
Both approaches require the specification of an expected effect size (i.e. a plausible range of predicted values 
based on previous studies, judgement or clinical significance), the published effect size (e.g. mean difference 
or log odds ratio) and standard error of this parameter. They also both assume that the sampling distribution 
of the parameter estimate is normally distributed (hence the need to use the natural logs of odds ratios). The 
natural log of the odds ratio is approximately normally distributed with known standard error given by 
√
1
𝐴
+
1
𝐵
+
1
𝐶
+
1
𝐷
, where A is the number of individuals in the experimental condition with the outcome of 
interest, B is the number of individuals in the experimental condition without the outcome of interest, and C 
and D reflect the number of individuals with and without the outcome of interest in the control condition 
respectively (i.e. Odds Ratio = (A/B)/(C/D)), provided that these numbers are not very small. For adjusted 
Odds Ratios, and/or where standard errors are not reported, 95% confidence intervals can be used to derive 
the standard error (i.e. [LN(upper confidence interval)-LN(lower confidence interval)]/3.92). 
In instances where the primary outcome measure is a continuous variable, standard errors can be derived 
for mean differences or regression coefficients (β) either using the standard formula for the SE of mean 
difference, i.e. [(SD2control/NControl)+(SD2experimental/Nexperimental)]; or t-test values using [Mean difference (or β)/t-
test value]; or 3) 95% Confidence Intervals: [LN(upper confidence interval)-LN(lower confidence 
interval)]/3.92).  
A worked example, using the calculator associated with Dienes, can be found in supplementary Appendix 1. 
Others have advocated alternative methods of computing Bayes Factors, including the Jeffreys-Zellner-Siow 
(JZS) t-test (4, 11) which can be implemented in R (12, 13) (see Dienes & McLatchie, submitted, for 
comparison). Moves have also been made towards full Bayesian modelling, which requires a much more 
advanced knowledge of R or specialist software packages, and is beyond the scope of the current paper (e.g. 
WinBUGS) (3, 10). 
Methods 
Bayes Factors were calculated for 12 randomised controlled trials published in the first six issues of Addiction 
in 2013 (between January and June). Effect sizes, standard errors, p–values, and the main conclusions drawn 
by the authors, were extracted from the papers for both primary and main secondary outcomes. Studies are 
generally only powered to detect estimated differences between experimental and control groups for the 
primary outcome, and thus Bayes Factors may be particularly useful for secondary analyses (14, 15). 
Concerns have previously been raised regarding the interpretation of non-significant findings for sensitivity 
analyses (14, 15). 
Adjusted effect sizes (where available) and those reported at the longest point of follow-up were used. Bayes 
Factors were calculated using the online calculator provided by Dienes (7) and the modified version using R 
code by Christie (8, 9). Predicted values for the effect size or population SD were based on previous studies 
(see Table 2). Additional sensitivity analyses were run to assess the effect of using higher and lower values. 
The chosen range was based either on the reported confidence interval of the predicted effect size selected 
from previous publications, or when not available, the opinion of the lead author as to what would be a 
plausible effect.  
When specifying the predicted effect, we used a ‘half normal distribution’ whose peak was at 0 (no effect) 
and extending upwards with a standard deviation equal to the expected effect size. This represents a 
hypothesis that the intervention had at least some positive effect with the effect being more likely to be 
smaller than larger. This is a conservative approach to prediction. Another approach would be to specify the 
hypothesis as a uniform distribution between 0 (or a minimally clinically significant value) and a plausible 
upper bound. Given that none of the authors of the studies reviewed indicated what they considered to be 
a clinically meaningful effect or a plausible upper bound for the effect size, we took the conservative 
approach. 
Results 
Out of the 12 studies, 55 non-significant effects and 20 significant effects were reported. For each of these, 
three Bayes Factors were calculated: one based on an expected population SD (identified from previous 
studies) and two based on a range of values around the expected population SD (identified from previous 
studies or based on expert opinion). Thus a total of 75 Bayes Factors were calculated in the main analysis and 
150 Bayes Factors were derived in the sensitivity analysis (see Table 2).  
Fifty-six per cent (n=42) of the Bayes Factors were between 1/3rd and 3; 14.7% (n=11) were < 1/3rd and 29.3% 
(n=22) were > 3. When considering only the non-significant findings (n=55), 20.0% (n=11) of Bayes Factors 
were < 1/3rd and 3.6% (n=2) were > 3. The other 76.4% (n=42) of Bayes Factors were between 1/3rd and 3. Of 
these, 26 were in the direction of there being an effect (Bayes Factor >1 & <3); 12 tended to favour the 
hypothesis of no effect (Bayes Factor <1 & >1/3rd); and for 4 there was no evidence either way (Bayes Factor 
=1).  
In sensitivity analyses, 13.3% of Bayes Factors were <1/3rd (n=20), 62.7% (n=94) were between 1/3rd and 3 
and 24.0% (n=36) were >3, showing good consistency with the main results. 
Authors either decided not to discuss results where p>0.05, to report them as non-significant, and/or to state 
that no association was found. Good concordance was noted between the online calculator  and the adapted 
R code (8), except for those Bayes Factors that indicated extreme evidence for the experimental hypothesis. 
Discussion 
Only 1/5th of all non-significant findings provided support for the hypothesis of no effect; while nearly 2/3rds 
of the Bayes Factors indicated data insensitivity. Thus, reporting ‘no difference’ between conditions or lack 
of associations was only appropriate for a small number of papers. A minority of Bayes Factors for the non-
significant effects also supported the experimental hypothesis; this tended to occur with p-values close to 
statistical significance.  
The development of online calculators and R code  means that researchers in the addiction field can easily 
calculate Bayes Factors to include as an adjunct to traditional frequentist results. The requirement to specify 
the experimental hypothesis means that scientific judgment is needed. This is a common criticism of Bayesian 
type methods (16), but it can also be a potential strength because it forces researchers to be specific about 
what it is they are testing. Moreover, if there are differences of view about what may be plausible values of 
the effect size, it is a simple matter to conduct sensitivity analyses to assess what difference this makes if 
any. As a rule of thumb, if one is interested in a clinically relevant range then the uniform distribution can be 
specified; alternatively one can use a half-normal distribution with the peak at 0 if one is interested in any 
effect at all and has little confidence in the likely value. To prevent researcher bias, pre-specified analysis 
plans may be published which detail the method which will be used to calculate Bayes Factors, the cut-off 
values for interpretation and the plausible effect size which is expected.  
The findings of this review show that researchers should avoid the use of terms such as ‘no difference’ or 
‘lack of associations’ for p-values >0.05, unless a Bayes Factor <0.3 is also found. Otherwise null findings 
should be framed as ‘the findings were inconclusive as to whether or not a difference/association was 
present’ or some similar wording. This is now encouraged practice by the journal, Addiction (1). Researchers 
may also wish to use Bayes Factors in order to quantify the evidence for the experimental hypothesis (i.e. 
moderate, strong, very strong and extreme) and/or use such a calculation as a stopping rule for data 
collection (17). For ethical and perhaps financial reasons interim analyses are often planned for randomised 
trials, with early stopping occurring if there is demonstrated efficacy, the intervention is harmful, or there is 
no beneficial effect. P-values cannot inform about us about the latter; in contrast a Bayes Factor indicating 
data insensitivity would suggest further recruitment, while a Bayes Factor indicating evidence for the null 
hypothesis may point towards early termination.  
Note that the methods used to derive Bayes Factors in this paper did not cover all the possibilities. More 
advanced Bayesian hierarchical modelling (BHM) (10), implemented in R and winBUGS, allows a wider range 
of distributions e.g. gamma, Poisson, binomial and negative binomial.  
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Table 2: Results, conclusions and corresponding Bayes Factors for RCTs published in the Journal of Addiction in the first 6 issues of 2013  
Study Intervention Control Participants Outcome Sample 
mean 
Sample 
standard 
error 
Significance 
p 
Study conclusions 
Results conclusions for non-significant findings 
Expected 
effect size 
 
Bayes factor: 
Dienes 
(Christie) (7-9) 
Interpretation of Bayes Factor using Dienes (7)  Interpretation of Bayes Factors using Jeffreys 
(2) 
Kypri (18) Web based 
alcohol screening 
and brief 
intervention for 
reducing 
hazardous 
drinking among 
Maori university 
students 
Screening only 6,697 students 
aged 17-24 
P: Frequency of alcohol consumption RaR 0.89 0.04 0.01** "Web-based screening and brief intervention 
reduced hazardous and harmful drinking among 
non-help-seeking Maori students" 
 
No mention of results >0.05 
 
RaR 0.91a 
RaR 0.85Ω 
RaR 0.97Ω 
17.5 (17.5) 
16.0  (16.0) 
5.3 (5.3) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Strong evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
P: Quantity of alcohol RaR 0.92 0.04 0.04* RaR 0.96a 
RaR 0.91Ω 
RaR 0.99Ω 
3.0 (3.0) 
3.4 (3.4) 
1.4 (1.4) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
P: Volume of alcohol RaR 0.78 0.06 <0.001*** RaR 0.89a 
RaR 0.82Ω 
RaR 0.96Ω 
261.6 (261.3) 
475.0 (466.2) 
13.2 (13.2) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Extreme evidence for experimental hypothesis 
Extreme evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
P: Academic Role Expectation and 
Alcohol Scale (AREAS) 
RaR 0.81 0.08 0.01* RaR 0.95a 
RaR 0.82Ω 
RaR 0.99Ω 
3.9 (3.9) 
13.1 (13.1) 
1.3 (1.3) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Binge drinking OR 0.80 0.12 0.06 OR 0.89a 
OR 0.65 Ω 
OR 0.99 Ω 
3.2 (3.2) 
2.8 (2.8) 
1.1 (1.1) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive 
Evidence is insensitive 
Moderate evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Heavy drinking OR 0.65 0.15 <0.001*** OR 0.55a 
OR 0.38 Ω 
OR 0.80 Ω 
19.0 (19.0) 
13.9 (13.9) 
15.5 (15.5) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Strong evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
Li (19) Methadone 
maintenance 
therapy (MMT) 
care intervention 
(with 
motivational 
interviewing) 
Standard care 41 providers and 
179 clients from 
six clinics 
P: Provider client interaction MD 4.82 2.23 0.033* “The MMT CARE intervention targeting providers in 
methadone maintenance clinics can improve 
providers' treatment knowledge and their 
interaction with clients. The intervention can also 
reduce clients' drug-using behaviour through 
motivational interviewing sessions conducted by 
trained providers . . . It is difficult to explain the 
unexpected findings in provider MMT knowledge 
and client drug avoidance self-efficacy [long term]; 
this may be a result of the small sample size and the 
pilot nature of the study" 
 
No mention of results >0.05 
 
MD 4.65b 
MD 2.18 Ω  
MD 7.01 Ω 
5.6 (5.6) 
4.2 (4.2) 
4.9 (4.9) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an 
effect)Evidence for experimental hypothesis (i.e. an 
effect) 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
P: MMT knowledge MD 1.00 0.56 0.544
  
MD 4.65b 
MD 2.18 Ω  
MD 7.01 Ω  
1.1 (1.1) 
2.1 (2.1) 
0.7 (0.7) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
 
P: Perceived stigma MD -1.87 2.31 0.421 MD -5.1c 
MD -1.2 Ω 
MD -9.0 Ω 
0.8 (0.8) 
1.2 (1.2) 
0.5 (0.5) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
P: Perceived client support MD 1.82 0.65 0.006** MD 4.65b 
MD 2.18 Ω  
MD 7.01 Ω 
12.9 (12.9) 
20.8 (20.8) 
8.9 (8.9) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Strong evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
P: Drug avoidance self-efficacy MD 1.25 1.24 0.312 MD 0.9d 
MD 0.3 Ω 
MD 1.5 Ω 
1.4 (1.4) 
1.2 (1.2) 
1.4 (1.3) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
P: Concurrent drug use OR 0.36 0.59 0.084 OR 0.66e 
OR 0.56Ω 
OR 0.78 Ω 
2.3 (2.3) 
2.7 (2.7) 
1.7 (1.7) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Ward (20) Behavioural 
support and 
nicotine 
replacement 
therapy (NRT) 
Behavioural 
support 
269 adults in four 
primary care 
clinics  
P: 12 month prolonged abstinence OR 0.51 0.50 0.182 “Nicotine patches may not be effective in helping 
smokers in low-income countries to stop when 
given as an adjunct to behavioural support . . . Our 
results do not support the incremental value of 
providing NRT in addition to behavioural 
counselling” 
 
“Between-group differences [for 12 month 
prolonged abstinence] were not statistically 
significant at follow-up . . .  No significant between-
group differences were found for seven-day point 
prevalence abstinence” 
OR 1.51f 
OR 1.35 Ω 
OR 1.70 Ω 
1.8 (1.8) 
1.6 (1.6) 
1.1 (1.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: 7-day point prevalence abstinence OR 0.69 0.32 >0.05 OR 1.78f 
OR 1.49 Ω 
OR 2.12 Ω 
1.4 (1.4) 
1.5 (1.5) 
1.2 (1.2) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Borland 
(21) 
OnQ: An 
interactive text 
messaging 
program 
Minimal 
intervention 
3530 smokers 
interested in 
quitting 
P: 6-months sustained abstinence OR 1.44 0.24 >0.05 “Smokers interested in quitting who were assigned 
randomly to an offer of wither the internet-based 
support program and/or the intervention 
automated text-messaging program had a non-
significantly greater odds of quitting for at least 6 
months than those randomised to an offer of a 
single website . . . we failed to find clear significant 
effects between the intervention and the control” 
 
“There were no differences in the proportion who 
reported making a quit attempt by the 1-month 
follow-up . . .  At the 7-month follow up, 8.5% of the 
sample achieved 6-month sustained abstinence. No 
significant differences were found by condition, but 
the control condition was numerically least 
successful”. 
OR 1.50g 
OR 1.20 α 
OR 1.80 α 
2.2 (2.2) 
2.0 (2.0) 
1.9 (1.9) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: 7-day point prevalence abstinence OR 1.20 0.15 >0.05 OR 1.50 g 
OR 1.20 α 
OR 1.80 α 
1.2 (1.2) 
1.6 (1.6) 
0.9 (0.9) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
S: Quit attempt OR 1.11 0.12 >0.05 OR 1.50 g 
OR 1.20 α 
OR 1.80 α 
0.6 (0.6) 
1.1 (1.1) 
0.4 (0.4) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
QuitCoach: 
Personalised 
tailored internet-
delivered advice 
program 
Minimal 
intervention 
P: 6-months sustained abstinence OR 1.40 0.24 >0.05 OR 1.50 g 
OR 1.20 α 
OR 1.80 α 
1.9 (1.9) 
1.8 (1.8) 
1.6 (1.6) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: 7-day point prevalence abstinence OR 1.03 0.15 >0.05 OR 1.50 g 
OR 1.20 α 
OR 1.80 α 
0.4 (0.4) 
0.7 (0.7) 
0.3 (0.3) 
Evidence is insensitive 
Evidence is insensitive 
Evidence for null hypothesis (i.e. no effect) 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for null hypothesis 
Moderate evidence for null hypothesis 
S: Quit attempt OR 0.91 0.12 >0.05 OR 1.50 g 
OR 1.20 α 
OR 1.80 α 
0.6 (0.6) 
1.0 (1.0) 
0.4 (0.4) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for null hypothesis 
No evidence 
Anecdotal evidence for null hypothesis 
Integration of 
onQ and 
QuitCoach 
Minimal 
intervention 
P: 6-months sustained abstinence OR 1.06 0.15 >0.05 OR 1.92 g 
OR 1.40 α 
OR 2.40 α 
0.3 (0.3) 
0.6 (0.6)  
0.2 (0.2) 
Evidence for null hypothesis (i.e. no effect) 
Evidence is insensitive 
Evidence for null hypothesis (i.e. no effect) 
Moderate evidence for null hypothesis 
Anecdotal evidence for null hypothesis 
Moderate evidence for null hypothesis 
S: 7-day point prevalence abstinence OR 1.45 0.24 >0.05 OR 1.92 g 
OR 1.40 α 
OR 2.40 α 
1.8 (1.8) 
2.3 (2.3) 
1.5 (1.5) 
Evidence is insensitive  
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Quit attempt OR 1.03 0.12 >0.05 OR 1.92 g 
OR 1.40 α 
OR 2.40 α 
0.2 (0.2) 
0.4 (0.4) 
0.2 (0.2) 
Evidence for null hypothesis (i.e. no effect) 
Evidence is insensitive 
Evidence for null hypothesis (i.e. no effect) 
Moderate evidence for null hypothesis 
Anecdotal evidence for null hypothesis 
Moderate evidence for null hypothesis 
Choice of either 
alone or 
combined 
program 
Minimal 
intervention 
P: 6-months sustained abstinence OR 1.47 0.24 >0.05 OR 1.92 g 
OR 1.40 α 
OR 2.40 α 
2.0 (2.0) 
2.5 (2.5) 
1.6 (1.6) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: 7-day point prevalence abstinence OR 1.07 0.15 >0.05 OR 1.92 g 
OR 1.40 α 
OR 2.40 α 
0.3 (0.3) 
0.6 (0.6) 
0.3 (0.3) 
Evidence for null hypothesis (i.e. no effect) 
Evidence is insensitive 
Evidence for null hypothesis (i.e. no effect) 
Moderate evidence for null hypothesis 
Anecdotal evidence for null hypothesis 
Moderate evidence for null hypothesis 
S: Quit attempt OR 1.15 0.12 >0.05 OR 1.92 g 
OR 1.40 α 
OR 2.40 α 
0.6 (0.6) 
1.0 (1.0) 
0.4 (0.4) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
 
 
Anecdotal evidence for null hypothesis 
No evidence 
Anecdotal evidence for null hypothesis 
Study Intervention Control Participants Outcome Sample 
mean 
Sample 
standard 
error 
Significance 
p 
Study conclusions 
Results conclusions for non-significant findings 
Expected 
effect size 
 
Bayes factor: 
Dienes 
(Christie) (7-9) 
Interpretation of Bayes Factor using Dienes (7)  Interpretation of Bayes Factors using Jeffreys 
(2) 
Rendall-
Mkosi (22) 
Motivational 
Interviewing 
Minimal 
intervention 
165 women aged 
18-44 years at risk 
of alcohol exposed 
pregnancy 
P: Alcohol exposed pregnancy OR 0.46 0.35 0.024* “A five session motivational interviewing 
intervention was found to be effective with women 
at risk of an alcohol-exposed pregnancy . . .  it is 
noteworthy that the reduction in risk for AEP in this 
study was mainly due to the improved 
contraceptive rather than a reduction in risky 
alcohol use” 
 
“At the 12-month follow-up, the reduction [in risky 
drinking] in the MI group (14.75%) was modestly 
larger when compared to the control group (10.94%), 
but this difference was also not statistically 
significant . . . the reduction in the proportion of 
participants who were using ineffective 
contraception at 12 months was no longer statically 
significant” 
OR 1.90h 
OR 1.36Ω 
OR 2.66Ω 
6.5 (6.5) 
4.2 (4.2) 
6.2 (6.2) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
S: Risky drinking OR 0.75 0.53 0.580 OR 0.84i 
OR 0.70 α 
OR 0.90 α 
1.1 (1.1) 
1.1 (1.1) 
1.1 (1.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Ineffective contraception OR 0.51 0.37 0.067 OR 0.63i 
OR 0.54 α 
OR 0.74 α 
3.0 (3.0) 
3.2 (3.2) 
2.6 (2.6) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Coffin (23) Aripiprazole Placebo 90 
methamphetamin
e dependent, 
sexually active 
adults from the 
community 
P: Methamphetamine use RR 0.88 0.15 0.410 “Compared with placebo, apripiprazole did not 
reduce methamphetamine use significantly among 
actively dependent adults . . . notwithstanding the 
promising pre-clinical results suggesting that 
apripiprazole might be effective at decreasing 
craving for methamphetamine and reducing it 
rewarding properties, we found no effect of this 
medication on methamphetamine use, severity of 
craving. We also did not evidence that apripiprazole 
was associated with increased methamphetamine 
use or rewards, as suggested by some 
investigators.” 
 
“In the intention-to-treat GEE analysis, the risk of 
testing positive for methamphetamine was similar in 
the aripiprazole arm compared to the placebo arm . . 
. difference between arms over follow-up was not 
significant [in severity of dependence . . . After 
controlling for imbalanced baseline characteristics, 
sexual risk behaviors declined similarly in the 
aripiprazole and placebo arms.” 
RR 1.12j 
RR 1.02 α 
RR 1.22 α 
1.3 (1.3) 
1.1 (1.1) 
1.1 (1.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Adherence – medication event 
monitoring systems 
RR 1.33 0.43 0.310 RR 0.99k 
RR 0.80 α 
RR 1.00 
1.0 (1.0) 
1.2 (1.2) 
0.7 (0.7) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
No evidence 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
S: Adherence – self-reported RR 0.59 0.49 0.170 RR 1.03k 
RR 1.01α 
RR 1.10 α 
1.1 (1.1) 
1.0 (1.0) 
1.2 (1.2) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
No evidence 
Anecdotal evidence for experimental hypothesis 
S: Number of partners with whom 
methamphetamines were used 
RR 0.38 0.86 0.254 RR 0.45k 
RR 0.24 Ω 
RR 0.82 Ω 
1.5 (1.5) 
1.4 (1.4) 
1.2 (1.2) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Number of sexual partners RR 0.69 0.46 0.418 RR 0.20k 
RR 0.04 Ω 
RR 0.93 Ω 
0.2 (0.2) 
0.1 (0.1) 
0.9 (0.9) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence is insensitive 
Strong evidence for null hypothesis 
Strong evidence for null hypothesis 
Anecdotal evidence for null hypothesis 
S: Episodes of anal and/or vaginal sex 
with sero-discordant partners 
RR 0.42 0.65 0.190 RR 0.31k 
RR 0.14 Ω 
RR 0.66 Ω 
1.7 (1.7) 
1.3 (1.3) 
1.7 (1.7) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Episodes of unprotected anal 
and/or vaginal sex with sero-
discordant partners 
RR 0.61 0.98 0.612 RR 0.34k 
RR 0.17 Ω 
RR 0.70 Ω 
0.9 (0.9) 
0.7 (0.7) 
1.1 (1.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Episodes of insertive unprotected 
anal sex with sero-discordant 
partners 
RR 0.54 0.72 0.385 RR 0.29k 
RR 0.14 Ω 
RR 0.58 Ω 
1.0 (1.0) 
0.8 (0.8) 
1.3 (1.3) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Episodes of receptive unprotected 
anal and/or vaginal sex with sero-
discordant partners 
RR 0.02 1.32 0.007** RR 0.27k 
RR 0.05 Ω 
RR 0.49 Ω 
12.0 (12.0) 
30.9 (30.9) 
4.4 (4.4) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Strong evidence for experimental hypothesis 
Very strong evidence for experimental 
hypothesis 
Moderate evidence for experimental hypothesis 
S: Methamphetamine craving  MD 6.8 7.65 0.380 MD 35k 
MD 8 Ω 
MD 62 Ω 
0.5 (0.5) 
1.3 (1.3) 
0.3 (0.3) 
Evidence is insensitive 
Evidence is insensitive 
Evidence for null hypothesis (i.e. no effect) 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for experimental hypothesis 
Strong evidence for null hypothesis 
S: Severity of dependence MD -0.04 0.85 0.960 MD 2.00l 
MD 1.00 α 
MD 3.00 α 
0.4 (0.4) 
0.7 (0.7) 
0.3 (0.3) 
Evidence is insensitive 
Evidence is insensitive 
Evidence for null hypothesis (i.e. no effect) 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for null hypothesis 
Strong evidence for null hypothesis 
S: Depression MD 1.47 2.19 0.500 MD 2.00l 
MD 1.00 α 
MD 3.00 α 
1.1 (1.1) 
1.2 (1.2) 
1.0 (1.0) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Gilbert (24) Tailored 
cessation on 
advice reports, 
including levels 
of reading ability 
Generic self-
help booklet 
58,66 current 
cigarette smokers 
aged 18-65 years, 
identified from 
general 
practitioner 
records 
P: Prolonged abstinence for 3 
months 
OR  1.18 0.13 0.184 “ESCAPE . . . appears to increase the rate at which 
smokers try to stop, but if there is an effect on 
prolonged abstinence it is small… Quit rates for the 
primary outcome of three months of prolonged 
abstinence were not significantly different between 
study groups. Thus, the intervention showed no 
effect. Quit rates in a number of different outcome 
measures of abstinence also showed no significant 
effect. However, all outcome measures showed a 
non-significant trend towards more abstinence in 
the intervention group” 
 
“The difference [in 3 month prolonged abstinence] 
was not significant. . . No significant differences were 
found between the intervention and control groups 
on shorter periods or on point-prevalence measures 
of abstinence”.  
OR 1.42m 
OR 1.21 Ω 
OR 1.68 Ω 
1.3 (1.3) 
1.7 (1.7) 
0.9 (0.9) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
S: Prolonged abstinence for 1 month OR 1.17 0.11 0.130 OR 1.42m 
OR 1.21 Ω 
OR 1.68 Ω 
1.5 (1.5) 
2.0 (2.0) 
1.1 (1.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: 7-day point prevalence abstinence OR 1.11 0.10 0.307 OR 1.42m 
OR 1.21 Ω 
OR 1.68 Ω 
0.8 (0.8) 
1.1 (1.1) 
0.5 (0.5) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
S: 24-hour point prevalence 
abstinence 
OR 1.15 0.09 0.131 OR 1.42m 
OR 1.21 Ω 
OR 1.68 Ω 
1.4 (1.4) 
2.1 (2.1) 
1.0 (1.0) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Quit attempt OR 1.11 0.06 0.074 OR 1.42m 
OR 1.21 Ω 
OR 1.68 Ω 
1.4 (1.4) 
2.3 (2.3) 
1.0 (1.0) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Alessi (25) Compensation 
for video 
Compensation 
for video 
30 adults who 
drank frequently 
P: Negative breath sample MD  20.20 5.74 <0.001*** MD 8.00n 
MD 5.00 α 
69.8 (69.9) 
21.7 (21.7) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Very strong evidence for experimental 
hypothesis 
recording alcohol 
breath tests 
using a cell 
phone and 
contingency 
management 
with escalating 
vouchers for on-
time alcohol-
negative tests. 
recording 
alcohol breath 
tests using a 
cell phone 
but were not 
physiologically 
dependent 
“Cellphone technology may be useful for extending 
contingency management to treatment for alcohol 
problems” 
 
No mention of results >0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MD 12.00 α 134.1 (134.2) Evidence for experimental hypothesis (i.e. an effect) Strong evidence for experimental hypothesis 
Extreme evidence for experimental hypothesis 
S: Longest duration of negative 
samples 
MD 10.90 3.52 <0.001*** MD 2.00n 
MD 1.00 α 
MD 3.00 α 
5.3 (5.3) 
2.2 (2.2) 
11.2 (11.2) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive  
Evidence for experimental hypothesis (i.e. an effect) 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
S: Days of drinking MD -11.00 3.48 <0.001*** MD 3.71o  
MD 1.00 α 
MD 7.00 α 
19.5 (19.5) 
2.3 (2.3) 
49.4 (49.4) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive  
Evidence for experimental hypothesis (i.e. an effect) 
Strong evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Very strong evidence for experimental 
hypothesis 
S: Drinks per drinking day MD -0.80 0.83 0.350 MD 1.20o 
MD 0.5 α 
MD 1.90 α 
1.2 (1.2) 
1.3 (1.3) 
1.0 (1.0) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
No evidence 
S: Addiction Severity Index MD -0.09 0.03 0.010** MD 0.10n 
MD 0.01 α 
MD 0.20 α 
41.3 (41.3) 
2.6 (2.6) 
28.0 (28.0) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive  
Evidence for experimental hypothesis (i.e. an effect) 
Very strong evidence for experimental 
hypothesis 
Anecdotal evidence for experimental hypothesis 
Very strong evidence for experimental 
hypothesis 
S: Drinker Inventory of Consequences  MD -0.80 0.23 <0.001*** MD 1.00p 
MD 0.2Ω 
MD 1.8 Ω 
120.0 (120.0) 
18.1 (18.1) 
83.4 (83.4) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
 
 
 
 
 
Extreme evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
Very strong evidence for experimental 
hypothesis 
 
Study Intervention Control Participants Outcome Sample 
mean 
Sample 
standard 
error 
Significance 
p 
Study conclusions 
Results conclusions for non-significant findings 
Expected 
effect size 
 
Bayes factor: 
Dienes 
(Christie) (7-9) 
Interpretation of Bayes Factor using Dienes (7)  Interpretation of Bayes Factors using Jeffreys 
(2) 
Richmond 
(26) 
Nortriptyline 
added to multi-
component 
smoking 
cessation 
intervention 
(included 
nicotine 
replacement 
therapy and 
cognitive 
behavioural 
therapy) 
Placebo added 
to multi-
component 
smoking 
cessation 
intervention 
(included 
nicotine 
replacement 
therapy and 
cognitive 
behavioural 
therapy) 
425 male 
prisoners 
P: Continuous abstinence  OR 0.98 0.30 >0.05 “Adding nortriptyline to a smoking cessation 
treatment package consisting of behavioural 
support and nicotine replacement therapy does not 
appear to improve long-term abstinence rates in 
male prisoners . . . In this study, we found no 
significant difference in an intention-to-treat 
analysis between the two study groups, suggesting 
that the additional use of NOR does not enhance 
quit rates for tobacco in the longer term” 
 
“Based on an intention-to-treat analysis and cut-off 
point for CO of < 10 p.p.m, continuous abstinence 
between the treatment and comparison groups were 
not statistically different at 3 months . . . point-
prevalence abstinence, using the < 5 p. p. m. cut-off 
between the treatment and control groups, was also 
not statistically significant different at three 
months”. 
OR 1.21q 
OR 1.01 Ω 
OR 1.55 Ω 
0.9 (0.9) 
1.0 (1.0) 
0.6 (0.6) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Moderate evidence for null hypothesis 
No evidence 
Moderate evidence for null hypothesis 
P: Point prevalence abstinence OR 0.81 0.29 >0.05 OR 1.21q 
OR 1.01 Ω 
OR 1.55 Ω 
1.1 (1.1) 
1.0 (1.0) 
1.0 (1.0) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
No evidence 
No evidence 
S: Smoking reduction (>50% 
reduction in cigarette consumption) 
OR 0.75 0.26 >0.05 OR 0.43q 
OR 0.12 Ω 
OR 0.99 Ω 
0.9 (0.9) 
0.4 (0.4) 
1.0 (1.0) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Moderate evidence for null hypothesis 
Moderate evidence for null hypothesis 
No evidence 
Levin (27) Venlafaxine-
extended release 
Placebo 103 cannabis 
dependent adults 
P: Two week abstinence OR 0.23 0.52 <0.001*** “For depressed, cannabis-dependent patients, 
venlafaxine-extended release does not appear to be 
effective at reducing depression and may lead to an 
increase in cannabis use” 
 
“No significant effect of treatment and no significant 
effect of baseline HAMD on 50% reduction of 
HAMD”. 
OR 0.80r 
OR 0.70 α 
OR  0.90 α 
2.9 (2.9) 
5.5 (5.5) 
1.6 (1.6) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
P: 50% reduction in depressive 
symptoms (Hamilton Depression 
rating scale) 
OR 0.75 0.42 0.510 OR 1.43s 
OR 1.20 α 
OR 1.60 α 
1.1 (1.1) 
1.1 (1.1) 
1.1 (1.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: THC urine levels  MD 964 320.27 <0.001*** MD 137.3t 
MD 100 α 
MD 300 α 
3.3 (3.3) 
2.3 (2.3) 
11.9 (11.9) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence is insensitive 
Evidence for experimental hypothesis (i.e. an effect) 
Moderate evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
S: Use in grams MD 2.67 4.72 0.320 MD 0.45u 
MD 0.02 α 
MD 0.88 α 
1.0 (1.0) 
1.0 (1.0)  
1.1 (1.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
No evidence 
No evidence 
Anecdotal evidence for experimental hypothesis 
Okuyemi 
(28) 
Motivational 
interviewing and 
nicotine patch 
Nicotine patch 
and brief advice 
to quit 
430 homeless 
smokers 
P: 7-day point prevalence abstinence OR 1.33 0.21 0.170 “Adding motivation interviewing counselling for 
nicotine patch did not increase smoking rate 
significantly at 26-week follow-up for homeless 
smokers . . . MI did not improve adherence 
measures among participants who received MI.” 
 
“Motivation for adherence scores at week 6 were 
marginally higher for participants in the intervention 
group than those in the control group . . . There were 
no differences between study groups in the 
proportion of participants who had their nicotine 
patches on at various study visits”. 
OR 1.35 v  
OR 1.02 Ω 
OR 1.78 Ω 
1.8 (1.8) 
1.1 (1.1) 
1.4 (1.4) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
S: Motivation to adhere MD 1.4 0.49 0.080 MD 4.97 w 
MD 1.19 Ω 
MD 8.75 Ω 
11.2 (11.2) 
25.0 (25.0) 
6.6 (6.6) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Strong evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
S:Self-efficacy to adhere MD 2.5 3.12 0.220 MD 4.97 w 
MD 1.19 Ω 
MD 8.75 Ω 
1.0 (1.0) 
1.2 (1.2) 
0.7 (0.7) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
S: Nicotine patch use OR 1.0 0.20 0.970 OR 1.14x 
OR 1.02 α 
OR 1.28 α 
0.8 (0.8) 
1.0 (1.0) 
0.6 (0.6) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Moderate evidence for null hypothesis 
No evidence 
Moderate evidence for null hypothesis 
Gustafson 
(29) 
Interest circle 
calls 
No intervention 201 clinics P: Waiting-time (mean days between 
first contact and first treatment) 
MD -0.24 2.12 0.911 “When trying to improve the effectiveness of 
addiction treatment services, clinic-level coaching 
appears to help improve waiting-time and number 
of new patients while other components of 
improvement collaboratives (interest circle calls and 
learning sessions) do not seem to add further value” 
 
“Learning sessions had a modest waiting time 
reduction while interest circle calls had a slight 
increase, but these two groups’ changes were not 
statistically significant . . . None of the groups 
showed significant improvement in retention for the 
6-month intervention period (Table 3a), or the entire 
intervention and sustainability period (Table 3b), and 
MD 10.6y 
MD 15 α 
MD 5 α 
0.2 (0.2) 
0.2 (0.2) 
0.4 (0.4) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence is insensitive 
Strong evidence for null hypothesis 
Strong evidence for null hypothesis 
Moderate evidence for null hypothesis 
 
P: Retention (percentage of patients 
retained from first to fourth 
treatment session) 
MD -0.003 0.03 0..912 MD 7.5y 
MD 10 α 
MD 5 α 
0.01 (0.01) 
0.00 (0.00) 
0.01 (0.01) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Very strong evidence for null hypothesis 
Extreme evidence for null hypothesis 
Very strong evidence for null hypothesis 
P: Annual number of new patients MD -0.04 0.04 0.369 MD 14.2y 
MD 20 α 
MD 10 α 
0.01 (0.01) 
0.00 (0.00) 
0.01 (0.00) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Very strong evidence for null hypothesis 
Extreme evidence for null hypothesis 
Very strong evidence for null hypothesis 
Coaching No intervention P: Waiting-time (mean days between 
first contact and first treatment) 
MD 4.86 1.95 0.013* there were no significant differences between 
groups” 
MD 10.6y 
MD 15 α 
MD 5 α 
7.2 (7.2) 
5.4 (5.4) 
10.7 (10.7) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Strong evidence for experimental hypothesis 
P: Retention (percentage of patients 
retained from first to fourth 
treatment session) 
MD 0.035 0.02 0.118 MD 7.5y 
MD 10 α 
MD 5 α 
0.0 (0.0) 
0.0 (0.0) 
0.0 (0.0) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Extreme evidence for null hypothesis 
Extreme evidence for null hypothesis 
Extreme evidence for null hypothesis 
P: Annual number of new patients MD 0.20 0.09 0.028* MD 0.14y 
MD 0.20 α 
MD 0.10 α 
6.0 (6.0) 
6.3 (6.3) 
5.0 (5.0) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Learning sessions No intervention P: Waiting-time (mean days between 
first contact and first treatment) 
MD 3.14 1.93 0.103 MD 10.6y 
MD 15 α 
MD 5 α 
1.2 (1.2) 
0.9 (0.9) 
2.1 (2.1) 
Evidence is insensitive 
Evidence is insensitive 
Evidence is insensitive 
Anecdotal evidence for experimental hypothesis 
Anecdotal evidence for null hypothesis 
Anecdotal evidence for experimental hypothesis 
P: Retention (percentage of patients 
retained from first to fourth 
treatment session) 
MD -0.003 0.02 0.899 MD 7.5y 
MD 10 α 
MD 5 α 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Extreme evidence for null hypothesis 
Extreme evidence for null hypothesis 
Extreme evidence for null hypothesis 
P: Annual number of new patients MD -0.001 0.07 0.982 MD 14.2y 
MD 20 α 
MD 10 α 
0.00 (0.00) 
0.00 (0.00) 
0.01 (0.01) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Extreme evidence for null hypothesis 
Extreme evidence for null hypothesis 
Very strong evidence for null hypothesis 
Combination No intervention P: Waiting-time (mean days between 
first contact and first treatment) 
MD 6.16 1.97 0.002** MD 10.6y 
MD 15 α 
MD 5 α 
41.2 (41.2) 
31.8 (31.8) 
50.4 (50.4) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect 
Very strong evidence for experimental 
hypothesis 
Very strong evidence for experimental 
hypothesis 
Very strong evidence for experimental 
hypothesis 
P: Retention (percentage of patients 
retained from first to fourth 
treatment session) 
MD -0.003 0.02 0.891 MD 7.5y 
MD 10 α 
MD 5 α 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Evidence for null hypothesis (i.e. no effect) 
Extreme evidence for null hypothesis 
Extreme evidence for null hypothesis 
Extreme evidence for null hypothesis 
P: Annual number of new patients MD 0.09 0.04 0.029* MD 0.14y 
MD 0.20 α 
MD 0.10 α 
5.6 (5.6) 
4.4 (4.4) 
6.5 (6.5) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect) 
Evidence for experimental hypothesis (i.e. an effect 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Moderate evidence for experimental hypothesis 
Note: P=primary outcome; S=secondary outcome; * significant at p<0.05; ** significant at p<0.01; *** significant at p<0.001; RaR=Rate ratio; RR= Relative risk; OR=Odds ratio; MD=mean difference; Ωrange of population SD reflects the CI of the expected effect size; α range of population SD based on opinion on a 
viable effect; a one directional relationship was assumed in all instances; Based on: a  (30); b (31) c (32) ; d  (33); e  (34); f (35); g  values specified in the sample size calculation; h  (36); i  (37); j  (38); k  (39); l  (40); m  (41); n  (42); o  (43); p  (44); q  (45);  r  (46); s  (47); t  (48); u  (49); v  (50); w (51); x  (52); y  values specified in 
the sample size calculation 
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 Supplementary Appendix 1 
We present here a worked example to show how to use Dienes’ online calculator to obtain Bayes Factors. 
http://www.lifesci.sussex.ac.uk/home/Zoltan_Dienes/inference/bayes_factor.swf 
Okuyemi et al  were interested in the effects of adding motivation interviewing (MI) counselling to the 
nicotine patch for smoking cessation among homeless smokers. They conducted a randomised controlled 
trial, whereby 430 participants were randomised to the intervention group or a control group. Verified seven-
day abstinence rates at week 26 for the intervention group was non-significantly higher than for the control 
group (OR 1.33; 95% CI=0.88, 2.02; p= 0.17). They concluded that “Adding motivational interviewing 
counselling to nicotine patch did not significantly increase smoking rate at 26-week follow-up for homeless 
smokers”. 
To calculate the Bayes Factor the odds ratio first needs to be transformed using a natural logarithmic 
transformation: 
LN(1.33)= 0.29 (2 dp) 
and the standard error calculated as: 
[LN(2.02)-LN(0.88)]/3.92= 0.21 (2 dp) 
We must then decide between three possible distributions to represent the predictions of the theory: 
uniform, normal or half-normal. If we can only specify a plausible maximum effect we should use the uniform 
distribution. In contrast, if a plausible predicted effect size can be specified we should opt for a normal or 
half-normal distribution. The choice between these depends on whether a directional hypothesis can be 
made, with the latter assuming a one-tailed test. In our example, a half-normal distribution is used as we 
hypothesize a positive impact of the intervention and can easily derive a predicted value from (50), which 
was a comprehensive meta-analysis of the use of MI for smoking cessation. This identified an OR for long-
term follow-up of 1.35 (95%CI 1.02 to 1.78), which translates to a log odds ratio of 0.30. 
We can now calculate our Bayes Factor. First mark the box ‘no’ next to ‘Is the distribution of p(population 
value|theory) uniform?’ 
 You will then see the following screen with three new boxes. These ask for the mean, standard deviation and 
number of tails (of a normal). As we are using a half-normal we set mean to 0 (Note: half-normal distribution 
has a mode of 0), SD to our plausible expected value (Note: this scales the half-normal distribution’s rate of 
drop) and tails to 1. We must also enter the standard error and mean of our sample. Then click "Go". 
 
 
This gives us a Bayes Factor of 1.82, indicating that the data favour the experimental hypothesis but not to a 
sufficient degree and are thus ‘insensitive’.  
 
 
 
